Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will be participating in the…

Source

Previous articleThe Premiere of our New Short Film Vital Psychedelic Training: Creating Worldwide Community
Next articlePT448 – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy